Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RGEN 
Repligen Corporation (RGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/03/2025: RGEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $187
1 Year Target Price $187
| 10 | Strong Buy |
| 4 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.98% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.45B USD | Price to earnings Ratio 7508.5 | 1Y Target Price 187 |
Price to earnings Ratio 7508.5 | 1Y Target Price 187 | ||
Volume (30-day avg) 19 | Beta 1.08 | 52 Weeks Range 102.97 - 182.52 | Updated Date 11/3/2025 |
52 Weeks Range 102.97 - 182.52 | Updated Date 11/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When - | Estimate 0.4137 | Actual 0.46 |
Profitability
Profit Margin 0.25% | Operating Margin (TTM) 8.89% |
Management Effectiveness
Return on Assets (TTM) 1.13% | Return on Equity (TTM) -0.68% |
Valuation
Trailing PE 7508.5 | Forward PE 74.07 | Enterprise Value 8147502862 | Price to Sales(TTM) 11.93 |
Enterprise Value 8147502862 | Price to Sales(TTM) 11.93 | ||
Enterprise Value to Revenue 12.09 | Enterprise Value to EBITDA 81.88 | Shares Outstanding 56257618 | Shares Floating 52659381 |
Shares Outstanding 56257618 | Shares Floating 52659381 | ||
Percent Insiders 6.38 | Percent Institutions 100.29 |
Upturn AI SWOT
Repligen Corporation
Company Overview
History and Background
Repligen Corporation was founded in 1981. Initially focused on protein A ligands, it has evolved into a leading provider of bioprocessing technologies, primarily used by biopharmaceutical companies. Significant milestones include acquisitions that expanded its product portfolio and market reach.
Core Business Areas
- Filtration: Repligen provides filtration products like tangential flow filtration (TFF) systems and filters used for separation and purification of biomolecules.
- Chromatography: This segment includes chromatography resins, columns, and systems used for purification of proteins and other biomolecules.
- Process Analytics: Repligen offers process analytics tools like chromatography systems and ELISA kits for monitoring and controlling bioprocessing operations.
- Cell Culture: Repligen also provides cell culture growth factors, and other products used in cell culture for drug discovery and antibody generation.
Leadership and Structure
Tony J. Hunt is the CEO. The company operates with a functional organizational structure, with key departments including R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Protein A Ligands: Repligen is a leading provider of Protein A ligands used in affinity chromatography for purifying antibodies. Competitors include Purolite and GE Healthcare (Cytiva). Market share estimated at ~40% of the protein A ligand market. Revenue from this product line is a key part of their chromatography revenue.
- OPUSu00ae Pre-packed Columns: OPUS pre-packed columns offer convenient and efficient purification for a range of biomolecules. Competitors include Cytiva and Tosoh Bioscience. Market share is estimated to be at ~15% in the pre-packed columns segment.
- KrosFlou00ae TFF Systems: KrosFlo TFF systems used for bioprocessing concentration and diafiltration. Competitors include Sartorius Stedim Biotech and Danaher(Pall Corporation). Repligen is estimated to hold ~30% of the TFF market. A portion of Filtration revenue comes from this product.
Market Dynamics
Industry Overview
The bioprocessing market is experiencing strong growth driven by increasing demand for biopharmaceuticals, including monoclonal antibodies and gene therapies. Key trends include automation, single-use technologies, and continuous manufacturing.
Positioning
Repligen is well-positioned as a key supplier of bioprocessing technologies, with a focus on innovative solutions that improve efficiency and reduce costs. Their competitive advantage lies in their specialized expertise and strong customer relationships.
Total Addressable Market (TAM)
The bioprocessing market's TAM is estimated to be around $25 billion. Repligen is positioned well to capture a significant portion of this TAM with its specialized technologies and solutions.
Upturn SWOT Analysis
Strengths
- Strong market position in protein A ligands
- Innovative product portfolio
- Strong customer relationships
- Experienced management team
- Proprietary technologies.
Weaknesses
- Reliance on a few key products
- Susceptible to technological disruptions
- Competition from larger players
- Geographic concentration in North America.
Opportunities
- Expanding into new bioprocessing areas (e.g., gene therapy)
- Acquiring complementary technologies
- Geographic expansion
- Increased adoption of single-use technologies
- Growth in emerging markets
Threats
- Increased competition
- Technological obsolescence
- Economic downturns
- Regulatory changes
- Supply Chain Disruptions
Competitors and Market Share
Key Competitors
- DHR
- SMTB
- WAT
Competitive Landscape
Repligen's advantages lie in its specialized expertise and strong customer relationships, however its size and concentration can be a limiting factor when compared to competitors.
Major Acquisitions
ARTeSYN Biosolutions
- Year: 2020
- Acquisition Price (USD millions): 200
- Strategic Rationale: Expanded single-use product portfolio and enhanced downstream bioprocessing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Repligen has experienced significant revenue growth in recent years, driven by strong demand for its bioprocessing products.
Future Projections: Analysts expect Repligen to continue to grow at a strong pace, driven by increasing demand for biopharmaceuticals. Consult analyst reports for detailed projections.
Recent Initiatives: Recent initiatives include acquisitions to expand its product portfolio, investments in R&D, and expansion of its manufacturing capacity.
Summary
Repligen is a strong player in the bioprocessing market, benefiting from increasing demand for biopharmaceuticals and a focus on innovative solutions. The company's strengths include its market position in protein A ligands and experienced management team, which is helping improve their financials and future outlook. They should continue to focus on single-use technologies and be wary of potential competitive pressures from larger companies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Repligen Corporation Investor Relations
- Industry Reports
- Analyst Estimates
- Company Filings
- Third party market research
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change, and actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repligen Corporation
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 1990-03-26 | President, CEO & Director Mr. Olivier Loeillot | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1778 | Website https://www.repligen.com |
Full time employees 1778 | Website https://www.repligen.com | ||
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.